BioLineRx Ltd. - American Depositary Shares (NQ:BLRX)

2.320 -0.050 (-2.11%)

Delayed Quote Updated: 12:10 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioLineRx Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To Know ↗

September 15, 2023

Via Benzinga

Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday ↗

September 15, 2023

B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to...

Via Benzinga

BioLineRx Ltd. (NASDAQ: BLRX) Leading the Way in Tuesday Trading Based on Percentage Gain

September 05, 2023

Via Investor Brand Network

Earnings Scheduled For August 30, 2023 ↗

August 30, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter.

Via Benzinga

A Preview Of BioLine Rx's Earnings ↗

August 29, 2023

Via Benzinga

A Preview Of BioLine Rx's Earnings ↗

March 21, 2023

Via Benzinga

3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now ↗

August 07, 2023

One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors.

Via InvestorPlace

3 Smart Penny Stocks with Huge Potential ↗

July 18, 2023

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023 ↗

June 29, 2023

If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead.

Via InvestorPlace

7 High-Potential Penny Stocks in the Biotech Sector ↗

May 04, 2023

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.

Via InvestorPlace

NASDAQ:BLRX Long Term Shareholder Alert: Investigation of Potential Wrongdoing at BioLineRx Ltd. ↗

April 24, 2023

San Diego, CA -- (SBWIRE) -- 04/24/2023 -- An investigation was announced for current long-term investors in shares of BioLineRx Ltd. (NASDAQ:BLRX) concerning potential breaches of fiduciary duties by...

Via SBWire

The 3 Best Biotech Stocks Under $1 to Buy for April ↗

April 04, 2023

While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider.

Via InvestorPlace

Earnings Scheduled For May 24, 2023 ↗

May 24, 2023

Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.

Via Benzinga

BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

March 06, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

BIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm

March 03, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)

March 03, 2023

From Law Offices of Frank R. Cruz

Via Business Wire

BLRX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

March 02, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avaya, BioLineRx, Enovix, and Southwest Airlines and Encourages Investors to Contact the Firm

March 01, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

BLRX DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

February 27, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avaya, BioLineRx, Enovix, and Southwest Airlines and Encourages Investors to Contact the Firm

February 24, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

BLRX FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

February 23, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

NASDAQ:BLRX Investor Notice: Deadline on March 6, 2023 in Lawsuit Against BioLineRx Ltd. Coming Up ↗

February 21, 2023

San Diego, CA -- (SBWIRE) -- 02/21/2023 -- A deadline is coming up on March 6, 2023 in the lawsuit filed for certain investors of BioLineRx Ltd. (NASDAQ:BLRX).

Via SBWire

ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

February 20, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Gaotu, Avaya, BioLineRx, and Enovix and Encourages Investors to Contact the Firm

February 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

February 16, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avaya, BioLineRx, Enovix, and Southwest Airlines and Encourages Investors to Contact the Firm

February 13, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

February 10, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

February 08, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX

February 06, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

February 03, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.